3:00  –  3.05 PM

Opening of the conference – Prof. Andrzej Grzybowski, MD, PhD, Foundation for Supporting the Development of Ophthalmology “Ophthalmology 21”, University of Warmia and Mazury, Olsztyn, Poland

3.05 – 3.21 PM

Introductory lecture – Myopia prevention and control: it is time to measure what we do, Prof. Serge Resnikoff, MD, PhD, The Chair of the International Myopia Institute

Session I

3.21 – 3.32 PM

Possible effect of Induced Spherical Aberrations (Z04) on Myopia Control by OrthoKeratology. Dr. Andriy Kovalov, MD, PhD. Ophthalmologist Consultant of AILAS Medical Center (Kyiv, Ukraine)

3.32 – 3.41 PM

Indications of favorable structural changes during ortho-k treatment. Dr. Trine Møldrup Jakobsen, MD, PhD, Department of Ophthalmology, University Hospital of Southern Denmark; Institution of Regional Research, University of Southern Denmark, Sønderborg, Denmark

3.41 – 3.50 PM

Twenty Years of Orthokeratology in Real Life: Efficacy, Safety and Predictors of Myopia Progression. Dr. Beata Tapasztó, MD, PhD, Semmelweis University, Department of Ophthalmology, Budapest, Hungary; Semmelweis University, Faculty of Health Sciences, Budapest, Hungary

3.50 – 4.00 PM

The evaluation of methods and the success of optical interventions in a real-world population. Dr. Mhairi Day PhD, the Department of Vision Sciences at Glasgow Caledonian University, Scotland, UK

4.00 – 4.10 PM

Myopia and strabismus. Prof. Pilar Merino Sanz, MD, PhD, Department of Ophthalmology, Hospital Universitario Gregorio Marañón, Madrid, Spain; President of the Spanish Society of Strabismus and Pediatric Ophthalmology (SEEOP)

4.10 – 4.20 PM

Raising the Bar in Myopia Control with MiYOSMART iQ: 12-month randomized controlled clinical trial results. Sylwia Kijewska, Hoya Lens Poland (sponsored lecture)

4.20 – 4.27 PM

Implementing Interdisciplinary Clinical Workflows in Modern Myopia Management, Max Aricochi, M.Sc., Eye Centre Kettenbrücke, Austria, the European Academy of Optometry and Optics.

4.27 – 4.39 PM

Early-life emmetropisation is independent of subsequent refractive error development. Dr. Sotiris Plainis, MSc, PhD, Laboratory of Optics and Vision, School of Medicine, University of Crete, Heraklion, Greece; Honorary Research Fellow at the University of Manchester, UK

4.39 – 4.49 PM

Choroidal thickness and myopia. Dr. Matteo Baldi MD, PhD Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health, University of Genoa, Italy.

4.49 – 5.00 PM

Empowering Clinical Excellence with Robust Evidence: Seven Key Facts of Essilor® Stellest® Lenses, Gabi Steenbekkers BOptom. FBCLA, Global Medical Advisor – Myopia, EssilorLuxottica (sponsored lecture)

5.00 – 5.15 PM

Discussion – Speakers and conference participants, moderated by Prof. Pilar Merino Sanz, MD, PhD, Department of Ophthalmology, Hospital Universitario Gregorio Marañón, Madrid, Spain; President of the Spanish Society of Strabismus and Pediatric Ophthalmology (SEEOP)

Session II (5:15 – 7:10 PM)

Reporting myopia-control efficacy as physiological axial growth and NNT (number needed to treat). Prof. Hakan Kaymak, MD, PhD, I.I.O. GbR, Düsseldorf, Germany; Gottfried O.H. Naumann Institute for Epidemiology and Prevention of Myopia, Saarland University, Homburg, Germany

Light-Based Interventions to Slow Myopia Progression: Current Evidence. Prof. Carla Lanca, PhD, New York University Abu Dhabi, UAE

Update on the Prevalence of Myopia in Europe. Prof. Miguel Á. Sánchez-Tena, PhD (Department of Optometry and Vision, Complutense University of Madrid, Spain) and Prof. Cristina Alvarez-Peregrina PhD (Complutense University of Madrid, Spain)

Association of time spent on near work and outdoors with the prevalence and progression of myopia. Prof. Olavi Pärssinen MD, PhD, CREAM Consortium, MRC Consortium, Finland

Who Should Be Treated for Myopia? Dr. Jelena Škunca Herman, MD, PhD, Department of Pediatric Ophthalmology and Strabismus, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

Population study – Myopia screening among first-grade students in Tromsø, Norway. Dr. Aleksandar Stojanovic, MD, PhD, FWCRS, University Hospital of North Norway, Tromsø, Norway; SynsLaser Surgery Clinics, Tromsø and Oslo, Norway

One-year efficacy and tolerability of 0.05% atropine for myopia control in Estonia, Teele Palumaa, MD, DPhil, Department of Ophthalmology, Emory University, USA, Institute of Genomics, University of Tartu, Estonia

Do children use myopia lenses as expected, Dr Pablo Concepción-Grande PhD, IOT Lenses and Szajna Soczewki Okularowe (sponsored lecture)

“Understanding Parental Perceptions and Barriers to Myopia Control Uptake” Dr Síofra Harrington, PhD, FAOI, FEAOO, Technological University Dublin, the Centre for Eye Research Ireland (CERI), Ireland

“The use of 0.01% atropine in myopia control.”  Prof. Andrzej Grzybowski, MD, PhD, Foundation for Supporting the Development of Ophthalmology “Ophthalmology 21”, University of Warmia and Mazury, Olsztyn, Poland (sponsored lecture)

Discussion – Speakers and conference participants, moderated by Prof. Andrzej Grzybowski, MD, PhD, Foundation for Supporting the Development of Ophthalmology “Ophthalmology 21”, University of Warmia and Mazury, Olsztyn, Poland

Closing of the conference – Prof. Andrzej Grzybowski, MD, PhD, Foundation for Supporting the Development of Ophthalmology “Ophthalmology 21”, University of Warmia and Mazury, Olsztyn, Poland